Market Overview

Barclays Increases Pfizer Price Target

Related PFE
3 Stocks In Focus As Biotech M&A Hopes For 2018 Rise
Pfizer Reports Updated Data From Phase III Study On Ibrance
Top Gaining 'Safer' Dividend Challengers Are Maiden, Tallgrass, And Schweitzer For December (Seeking Alpha)

In a report released Wednesday, Barclays analyst Mark Purcell increases his price target for Pfizer (NYSE: PFE) from $32 to $34 per share, maintaining an Equal-Weight rating.

Analyst at Barclays are more bullish on the pharmaceutical sector, favoring Pfizer's potential for organic growth. Purcell mentions Pfizer's near-term potential depends on the company's ability to change its tax structure, increase transactions through core operations and increase its pipeline to full potential.

Shares of Pfizer are up about one percent.

Latest Ratings for PFE

Oct 2017BMO CapitalMaintainsOutperform
Sep 2017Morgan StanleyUpgradesEqual-WeightOverweight
Aug 2017BMO CapitalUpgradesMarket PerformOutperform

View More Analyst Ratings for PFE
View the Latest Analyst Ratings

Posted-In: Barclays Mark PurcellPrice Target Analyst Ratings


Related Articles (PFE)

View Comments and Join the Discussion!

Partner Center